Eli Lilly Company pharmaceutical medications, products and
September 6 2016 by Ray Sahelian, M.D.
Eli Lilly is a leading drug company developing a growing portfolio of pharmaceutical products that treat depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions.
Why you cant trust medical articles in journals
Lilly ‘Ghostwrote’ Articles to Market Drug, Files Say
It was reported on Bloomberg News that, "Eli Lilly & Co. pharmaceutical company officials wrote medical journal studies about the antipsychotic Zyprexa and then asked doctors to put their names on the articles, a practice called “ghostwriting,” according to unsealed company files. Lilly employees also compiled a guide to hiring scientists to write favorable articles, complained to journal editors when publication was delayed and submitted rejected articles to other outlets, according to documents filed in drug-overpricing suits against the Indianapolis-based company, the largest manufacturer of psychiatric medicines.
Comments: Doctors get a number of free medical journals for free each week, and some of these articles are, in my opinion, biased towards medications promoted by drug companies that take out ads in these magazines or pay doctors to write favorable articles.
Eli Lilly pharmaceutical products
Gemzar (gemcitabine hydrochloride)
Actos (pioglitazone hydrochloride)
A U.S. jury in April 2014 ordered Takeda Pharmaceutical to pay $6 billion in damages over claims that it concealed cancer risks associated with its Actos diabetes drug. The massive award was met with "stunned silence" in the packed Lafayette, Louisiana, courtroom, plaintiffs' lawyer Mark Lanier said. Eli Lilly, Takeda's co-defendant, was ordered to pay $3 billion in punitive damages.
Byetta (exenatide) injection - Acute pancreatitis has been added as a precaution to the label of exenatide (Byetta) based on an FDA review of post-marketing reports.
Humulin (human insulin [rDNA origin])
Humalog (insulin lispro injection [rDNA origin])
Humalog Mix75/25 (75% Insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin])
Humulin Pen (human insulin [rDNA origin]) & Humalog® Pen (insulin lispro [rDNA origin])
Humatrope (somatropin rDNA origin for injection, Lilly)
Evista (raloxifene hydrochloride)
Xigris (drotrecogin alfa [activated])
Cymbalta (duloxetine hydrocholoride)
Prozac (fluoxetine hydrochloride)
Strattera (atomoxetine hydrochloride)
Symbyax (olanzapine and fluoxetine hydrochloride)
Zyprexa (olanzapine) - Drug giant Eli Lilly has engaged in a decade-long effort to play down the health risks of its top-selling medication, the schizophrenia drug Zyprexa, The New York Times reported in December 2006. Citing hundreds of internal Lilly documents and e-mail messages among top Eli Lilly company managers provided by a lawyer representing mentally ill patients, the Times said Eli Lilly executives kept important information from doctors about the link of Zyprexa to obesity and elevated blood sugar, risk factors for diabetes. The drug company's own published data, which it told sales representatives to play down in conversations with doctors, showed 30 percent of patients taking Zyprexa gain 22 pounds or more after a year on the drug, with some reporting gaining 100 pounds or more. With sales of $4.2 billion in 2005, Zyprexa is by far the best-selling product for Eli Lilly, with some two million people worldwide taking it. Eli Lilly agreed in 2005 to pay $750 million to settle suits by 8,000 people who claimed they developed diabetes or other medical problems after taking Zyprexa; thousands more suits are pending.
January 2007 -
Eli Lilly and Co. has agreed to settle the majority of cases brought against the
company by patients claiming its antipsychotic drug Zyprexa caused them to
develop diabetes. Eli Lilly said it will take a charge of up to $500 million in
the fourth quarter to cover more than 18,000 claims -- substantially less than
the $700 million it agreed to pay to settle about 8,000 claims in June 2005.
Revenue from Zyprexa, the biggest product by Eli Lilly, fell sharply in 2005 due
to concerns over the drug's tendency to cause weight gain -- a major risk factor
for development of diabetes.
The Zyprexa issue isn't over. About 1,200 claims are not included in the settlements and will go to trial, beginning in April, 2007 in the U.S. District Court for the Eastern District of New York. Most of the plaintiffs' claims stated that before September 2003, the package insert warning of a potential link between Zyprexa and elevated blood sugar or diabetes was not sufficiently clear. Eli Lilly published data, which it told sales representatives to play down in conversations with doctors, showed 30 percent of patients taking Zyprexa gain 22 pounds or more after a year on the drug, with some reporting gains of 100 pounds or more, the Times said in its front-page article.
Zyprexa suit, Connecticut, 2008
The state of Connecticut has filed suit against Eli Lilly accusing the drugmaker of illegally marketing and hiding serious side effects of its chizophrenia drug Zyprexa. Attorney General Richard Blumenthal wants to recover millions of taxpayer and consumer dollars improperly spent on Zyprexa as a result of its illegal marketing, and millions more spent for treatment of serious side effects from Zyprexa.
Arxxant - Eli Lilly and Co. says its once-daily experimental pill Arxxant reduces vision loss by 40 percent, compared with placebo, in a 3-year late-stage trial of patients with moderate-to-severe diabetic retinopathy. Diabetic retinopathy, an eye-threatening condition in which diabetes damages small blood vessels in the retina, affects more than 4 million Americans age 40 and older. It is the leading cause of blindness among working-age adults. Indianapolis-based Eli Lilly said vision loss -- defined as a three-line loss on a standard eye chart that continues for at least 6 months -- occurred in 5.5 percent of patients treated with Arxxant, the chemical name for which is ruboxistaurin. That compared with 9 percent of patients given placebos during the study. The 40 percent reduced risk for Arxxant in the 685-patient trial was statistically significant.